Literature DB >> 7818999

Racial incidence of hemolytic uremic syndrome.

S M Jernigan1, F B Waldo.   

Abstract

Hemolytic uremic syndrome (HUS) is the most common cause of acute renal failure in children and is caused by infection with verotoxin-producing Escherichia coli. There is no consensus on the relative incidence of HUS in blacks and whites. An equal racial incidence has been reported by two centers with small black populations. A series from Washington D.C. reported a low incidence in blacks. The population of Alabama is 32% black and 66% white. The Children's Hospital of Alabama admission rate has a similar racial distribution (35% black, 65% white). A record review from 1980-1992 identified 45 patients with HUS; 43 (96%) were white and only 2 (4%) were black. Based on census data for Alabama in 1980 and 1990, this gives an average annual incidence of HUS of 0.45 per 100,000 in whites and of 0.043 per 100,000 in blacks (P < 0.001, Fischer's exact test). Similar results were found in the group of patients with HUS and a history of diarrhea; whites 0.39 and blacks 0.02 (P < 0.001). However, in those with no history of diarrhea there was no significant racial difference: whites 0.05 and blacks 0.02. There were too few blacks to compare clinical course and outcome. We conclude that typical diarrhea-associated HUS is a relatively rare disease in blacks compared with whites. The reasons are unclear.

Entities:  

Mesh:

Year:  1994        PMID: 7818999     DOI: 10.1007/bf00858122

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  12 in total

1.  THE HEMOLYTIC-UREMIC SYNDROME.

Authors:  C GIANANTONIO; M VITACCO; F MENDILAHARZU; A RUTTY; J MENDILAHARZU
Journal:  J Pediatr       Date:  1964-04       Impact factor: 4.406

Review 2.  The epidemiology of infections caused by Escherichia coli O157:H7, other enterohemorrhagic E. coli, and the associated hemolytic uremic syndrome.

Authors:  P M Griffin; R V Tauxe
Journal:  Epidemiol Rev       Date:  1991       Impact factor: 6.222

3.  The haemolytic-uraemic syndrome: a report of ten cases treated in Nairobi.

Authors:  P Tdavies
Journal:  East Afr Med J       Date:  1968-03

4.  The haemolytic-uraemic syndrome: a survey in Southern Africa.

Authors:  M A Kibel; P J Barnard
Journal:  S Afr Med J       Date:  1968-07-13

5.  The epidemiology and clinical aspects of the hemolytic uremic syndrome in Minnesota.

Authors:  D L Martin; K L MacDonald; K E White; J T Soler; M T Osterholm
Journal:  N Engl J Med       Date:  1990-10-25       Impact factor: 91.245

6.  Hemolytic-uremic syndrome: a population-based study in Washington, DC and Baltimore, Maryland.

Authors:  J S Kinney; T P Gross; C C Porter; M F Rogers; L B Schonberger; E S Hurwitz
Journal:  Am J Public Health       Date:  1988-01       Impact factor: 9.308

Review 7.  Hemolytic-uremic syndrome.

Authors:  W L Robson; A K Leung; B S Kaplan
Journal:  Curr Probl Pediatr       Date:  1993-01

8.  A population-based study of hemolytic-uremic syndrome in Oregon, 1979-1982.

Authors:  M F Rogers; G W Rutherford; S R Alexander; J H DiLiberti; L Foster; L B Schonberger; E S Hurwitz
Journal:  Am J Epidemiol       Date:  1986-01       Impact factor: 4.897

9.  Epidemiology of hemolytic-uremic syndrome in Canadian children from 1986 to 1988. The Canadian Pediatric Kidney Disease Reference Centre.

Authors:  P C Rowe; E Orrbine; G A Wells; P N McLaine
Journal:  J Pediatr       Date:  1991-08       Impact factor: 4.406

10.  Hemolytic uremic syndrome epidemiology: a population-based study in King County, Washington, 1971 to 1980.

Authors:  P I Tarr; R O Hickman
Journal:  Pediatrics       Date:  1987-07       Impact factor: 7.124

View more
  2 in total

1.  Racial incidence of hemolytic-uremic syndrome.

Authors:  K J Sheth; J C Gill; P L Havens; H E Leichter
Journal:  Pediatr Nephrol       Date:  1995-06       Impact factor: 3.714

Review 2.  Infection by Shiga toxin-producing Escherichia coli: an overview.

Authors:  Mohamed A Karmali
Journal:  Mol Biotechnol       Date:  2004-02       Impact factor: 2.695

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.